Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology

Abstract

Cardio-oncology is a clinical/scientific discipline which aims to prevent and/or treat cardiovascular diseases in cancer patients. Although a large number of cancer treatments are known to cause cardiovascular toxicity, they are still widely used because they are highly effective. Unfortunately, therapeutic interventions to prevent and/or treat cancer treatment-induced cardiovascular toxicity have not been established yet. A major challenge for such interventions is to protect the cardiovascular system without compromising the therapeutic benefit of anticancer medications. Intriguingly, the polyphenolic natural compound resveratrol and its analogs have been shown in preclinical studies to protect against cancer treatment-induced cardiovascular toxicity. They have also been shown to possess significant anticancer properties on their own, and to enhance the anticancer effect of other cancer treatments. Thus, they hold significant promise to protect the cardiovascular system and fight the cancer at the same time. In this review, we will discuss the current knowledge regarding the cardio-protective and the anticancer properties of resveratrol and its analogs. Thereafter, we will discuss the challenges that face the clinical application of these agents. To conclude, we will highlight important gaps of knowledge and future research directions to accelerate the translation of these exciting preclinical findings to cancer patient care.

Sexual Dimorphism in Doxorubicin-induced Systemic Inflammation: Implications for Hepatic Cytochrome P450 Regulation

“…Furthermore, systemic inflammatory reaction is associated with poor outcomes in cancer patients [25], which may be attributed to the role of interleukins in mediating progression, metastatic processes, and drug resistance of cancer cells [26]. Indeed, nutraceuticals with anti-inflammatory properties such as lycopene, curcumin, and resveratrol have been shown to reduce the toxicity and improve the efficacy of chemotherapeutic agents [14,27]. We and others have reported significant sex-related differences in acute and chronic DOX-induced cardiotoxicity and nephrotoxicity in experimental animals [11,[28][29][30][31][32].…”

Cardiovascular Vulnerability to COVID-19 in Cancer Survivors

“…Nevertheless, subclinical cardiotoxicity occurs in those who receive even low doses of anthracyclines [39][40][41]. The mechanisms of anthracycline-induced cardiotoxicity include oxidative stress [42], apoptotic and necrotic cell death [43,44], cellular senescence [45][46][47] Other cardiotoxic cancer treatments include tyrosine kinase inhibitors, trastuzumab, immune check point inhibitors, cyclophosphamide, and cisplatin (reviewed in [29,30]).…”

“…Nearly 50% of pediatric cancer patients receive anthracyclines such as doxorubicin (DOX), which are known to cause cardiotoxicity [28]. Other cancer treatments may cause varying degrees of cardiotoxicity (reviewed in [29,30]). Radiation therapy can also lead to cardiovascular complications including coronary artery disease, cardiomyopathy, and myocardial fibrosis [31,32].…”

Role of resveratrol in cardiovascular and associated diseases.

“…Red wine contains resveratrol with different polyphenols. Many experimental trials have confirmed, phytochemical; resveratrol protects against in heart failure, cancer and other associated diseases like diabetes-cardiac, cardio-oncology and obesity caused by oxidative stress or secondary disease function [3] as they have become overwhelmed the global health [4]. A short term disclosure of resveratrol with high dosages shows extraordinary cardioprotective results [5].…”